2026-06-30T03:57:01Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/182392024-11-28T14:55:20Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16982
Repisalud author Boughanem, Hatim author Yubero-Serrano, Elena M. author López-Miranda, José author Tinahones, Francisco J. author Macias-Gonzalez, Manuel authoraffiliation [Boughanem,H; Tinahones,FJ; Macias-Gonzalez,M] Department of Endocrinology and Nutrition, Institute of Biomedical Research Institute in Malaga (IBIMA), Virgen de la Victoria University Hospital, Málaga, Spain. [Yubero-Serrano,EM; López-Miranda,J] Lipids and Atherosclerosis Unit, Maimonides Institute for Biomedical Research in Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain. [Yubero-Serrano,EM; López-Miranda,J; Tinahones,FJ; Macias-Gonzalez,M] CIBEROBN (CIBER in Physiopathology of Obesity and Nutrition), Instituto de Salud Carlos III, Madrid, Spain. 2024-02-19T15:24:50Z 2024-02-19T15:24:50Z 2021-01-24 10.3390/ijms22031133 1422-0067 International Journal of Molecular Sciences http://hdl.handle.net/10668/4187 33498859 http://hdl.handle.net/20.500.12105/18239 Evidence from observational and in vitro studies suggests that insulin growth-factor-binding protein type 2 (IGFBP2) is a promising protein in non-communicable diseases, such as obesity, insulin resistance, metabolic syndrome, or type 2 diabetes. Accordingly, great efforts have been carried out to explore the role of IGFBP2 in obesity state and insulin-related diseases, which it is typically found decreased. However, the physiological pathways have not been explored yet, and the relevance of IGFBP2 as an important pathway integrator of metabolic disorders is still unknown. Here, we review and discuss the molecular structure of IGFBP2 as the first element of regulating the expression of IGFBP2. We highlight an update of the association between low serum IGFBP2 and an increased risk of obesity, type 2 diabetes, metabolic syndrome, and low insulin sensitivity. We hypothesize mechanisms of IGFBP2 on the development of obesity and insulin resistance in an insulin-independent manner, which meant that could be evaluated as a therapeutic target. Finally, we cover the most interesting lifestyle modifications that regulate IGFBP2, since lifestyle factors (diet and/or physical activity) are associated with important variations in serum IGFBP2. eng IGFBP2 Obesity Insulin resistance Lifestyle modification Epigenetic Proteína 2 de unión a factor de crecimiento similar a la insulina Obesidad Resistencia a la insulina Estilo de vida Epigénesis genética Potential Role of Insulin Growth-Factor-Binding Protein 2 as Therapeutic Target for Obesity-Related Insulin Resistance research article